About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Overview

The Manager, US Commercial Analytics is a hands-on analytical role responsible for delivering actionable regional, territory, and account-level insights that drive Amtagvi and Proleukin commercial performance. As the primary analytics partner to the US field organization, you will translate business questions into analyses, build dashboards and analytical models, and recommend actions that improve field deployment, targeting, and engagement across the growing network of Authorized Treatment Centers (ATCs). You will connect commercial demand signals with operational execution, supporting both current marketed products and upcoming indication launches. This opportunity is suited to an experienced analyst from a biotechnology or pharmaceutical company or a consulting role serving these clients who wants to own analytical work from business question through recommendation and follow-up.

Essential Functions and Responsibilities

Sub-National & Territory Analytics

Design, build, and maintain territory-level performance dashboards and scorecards for the US field organization, incorporating ATC-level infusion data, referral patterns, and patient flow metrics
Develop and execute sub-national analyses including geographic demand modeling, ATC penetration analytics, and regional market opportunity assessments
Perform territory alignment and optimization analyses to support field force deployment decisions as the ATC network scales beyond 110 centers
Create ATC-level performance profiles integrating specialty pharmacy data, claims data, patient hub data, and CRM activity to identify growth opportunities and underperforming territories
Deliver ad-hoc analytical support to Regional Business Directors and Account Managers: clarify the business question, select the analytical approach, validate findings, and translate results into actionable territory-level recommendations; follow up with business partners to assess decisions and outcomes

Field Force Effectiveness

Design and manage field force effectiveness measurement frameworks, including call activity analytics, reach and frequency optimization, and engagement scoring for ATC-based selling
Develop targeting and segmentation models for the ATC network, incorporating physician-level prescribing potential, patient referral patterns, and competitive dynamics
Support incentive compensation plan design, modeling, and quarterly payout calculations in partnership with Sales Operations and HR
Build and maintain call planning tools and next-best-action frameworks tailored to the unique cell therapy commercial model
Conduct field force sizing and structure analyses to inform deployment decisions for new indication launches (NSCLC, endometrial cancer, sarcomas)